Discrepant performance on oral and intravenous glucose tolerance tests

The role of gastric inhibitory polypeptide

D. Elahi, Dana Andersen, J. D. Tobin, R. Andres

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Analysis of a large study population revealed a group of eight healthy men whose tolerance to oral glucose was markedly greater than their tolerance to iv glucose (disparate group). The physiological basis of the anomalous performance was investigated using a variation of the hyperglycemic glucose clamp technique. This technique allows separation of the effects of hyperglycemia and intestinal insulinotropic factors on B-cell response. The eight subjects with disparate tolerance tests were compared to eight healthy control subjects whose tolerances on the two tests were very similar. The disparate performers showed 1) higher basal circulating gastric inhibitory polypeptide (GIP) levels, 2) lower immunoreactive insulin (IRI) responses to hyperglycemia (iv glucose alone), 3) enhanced GIP response to oral glucose, and 4) enhanced IRI response to oral glucose. These results may be interpreted as indicating a role for GIP in the improved tolerance for oral glucose, although other unknown gastrointestinal hormones could theoretically also be involved. Enhanced release of GIP after oral glucose may compensate for the reduced IRI release in response to hyperglycemia. The mechanism underlying the enhanced GIP response in these studies remains to be explored. It will be of interest to follow these subjects to see whether their anomalous gut β-cell balance has any long term pathogenetic implications.

Original languageEnglish (US)
Pages (from-to)1199-1203
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume52
Issue number6
StatePublished - 1981
Externally publishedYes

Fingerprint

Gastric Inhibitory Polypeptide
Glucose Tolerance Test
Glucose
Hyperglycemia
Insulin
Gastrointestinal Hormones
Glucose Clamp Technique
Healthy Volunteers
B-Lymphocytes
Clamping devices
Cells
Population

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Discrepant performance on oral and intravenous glucose tolerance tests : The role of gastric inhibitory polypeptide. / Elahi, D.; Andersen, Dana; Tobin, J. D.; Andres, R.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 52, No. 6, 1981, p. 1199-1203.

Research output: Contribution to journalArticle

@article{fcf366448aad4d2fba1d480dc7a6100a,
title = "Discrepant performance on oral and intravenous glucose tolerance tests: The role of gastric inhibitory polypeptide",
abstract = "Analysis of a large study population revealed a group of eight healthy men whose tolerance to oral glucose was markedly greater than their tolerance to iv glucose (disparate group). The physiological basis of the anomalous performance was investigated using a variation of the hyperglycemic glucose clamp technique. This technique allows separation of the effects of hyperglycemia and intestinal insulinotropic factors on B-cell response. The eight subjects with disparate tolerance tests were compared to eight healthy control subjects whose tolerances on the two tests were very similar. The disparate performers showed 1) higher basal circulating gastric inhibitory polypeptide (GIP) levels, 2) lower immunoreactive insulin (IRI) responses to hyperglycemia (iv glucose alone), 3) enhanced GIP response to oral glucose, and 4) enhanced IRI response to oral glucose. These results may be interpreted as indicating a role for GIP in the improved tolerance for oral glucose, although other unknown gastrointestinal hormones could theoretically also be involved. Enhanced release of GIP after oral glucose may compensate for the reduced IRI release in response to hyperglycemia. The mechanism underlying the enhanced GIP response in these studies remains to be explored. It will be of interest to follow these subjects to see whether their anomalous gut β-cell balance has any long term pathogenetic implications.",
author = "D. Elahi and Dana Andersen and Tobin, {J. D.} and R. Andres",
year = "1981",
language = "English (US)",
volume = "52",
pages = "1199--1203",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Discrepant performance on oral and intravenous glucose tolerance tests

T2 - The role of gastric inhibitory polypeptide

AU - Elahi, D.

AU - Andersen, Dana

AU - Tobin, J. D.

AU - Andres, R.

PY - 1981

Y1 - 1981

N2 - Analysis of a large study population revealed a group of eight healthy men whose tolerance to oral glucose was markedly greater than their tolerance to iv glucose (disparate group). The physiological basis of the anomalous performance was investigated using a variation of the hyperglycemic glucose clamp technique. This technique allows separation of the effects of hyperglycemia and intestinal insulinotropic factors on B-cell response. The eight subjects with disparate tolerance tests were compared to eight healthy control subjects whose tolerances on the two tests were very similar. The disparate performers showed 1) higher basal circulating gastric inhibitory polypeptide (GIP) levels, 2) lower immunoreactive insulin (IRI) responses to hyperglycemia (iv glucose alone), 3) enhanced GIP response to oral glucose, and 4) enhanced IRI response to oral glucose. These results may be interpreted as indicating a role for GIP in the improved tolerance for oral glucose, although other unknown gastrointestinal hormones could theoretically also be involved. Enhanced release of GIP after oral glucose may compensate for the reduced IRI release in response to hyperglycemia. The mechanism underlying the enhanced GIP response in these studies remains to be explored. It will be of interest to follow these subjects to see whether their anomalous gut β-cell balance has any long term pathogenetic implications.

AB - Analysis of a large study population revealed a group of eight healthy men whose tolerance to oral glucose was markedly greater than their tolerance to iv glucose (disparate group). The physiological basis of the anomalous performance was investigated using a variation of the hyperglycemic glucose clamp technique. This technique allows separation of the effects of hyperglycemia and intestinal insulinotropic factors on B-cell response. The eight subjects with disparate tolerance tests were compared to eight healthy control subjects whose tolerances on the two tests were very similar. The disparate performers showed 1) higher basal circulating gastric inhibitory polypeptide (GIP) levels, 2) lower immunoreactive insulin (IRI) responses to hyperglycemia (iv glucose alone), 3) enhanced GIP response to oral glucose, and 4) enhanced IRI response to oral glucose. These results may be interpreted as indicating a role for GIP in the improved tolerance for oral glucose, although other unknown gastrointestinal hormones could theoretically also be involved. Enhanced release of GIP after oral glucose may compensate for the reduced IRI release in response to hyperglycemia. The mechanism underlying the enhanced GIP response in these studies remains to be explored. It will be of interest to follow these subjects to see whether their anomalous gut β-cell balance has any long term pathogenetic implications.

UR - http://www.scopus.com/inward/record.url?scp=0019736391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019736391&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 1199

EP - 1203

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -